Shots:
In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers
Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer
PharmaShots presents a concise…
Shots:
The EMA approved 9 New Chemical Entity (NCE) and 5 Biologic Drugs in July 2023, leading to treatments for patients and advances in the healthcare industry
In July 2023, the major highlights drugs were Soliris approval for refractory generalised myasthenia gravis and Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
PharmaShots has compiled a list…

